VORAPAXAR for Cardiovascular event prophylaxis: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 7 adverse event reports in the FDA FAERS database where VORAPAXAR was used for Cardiovascular event prophylaxis.
Most Reported Side Effects for VORAPAXAR
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Gastrointestinal haemorrhage | 15 | 7.9% | 1 | 7 |
| Epistaxis | 11 | 5.8% | 0 | 1 |
| Chest pain | 8 | 4.2% | 0 | 4 |
| Death | 8 | 4.2% | 8 | 0 |
| Drug dose omission | 8 | 4.2% | 0 | 1 |
| Haemorrhage | 7 | 3.7% | 0 | 2 |
| Dyspnoea | 6 | 3.2% | 0 | 4 |
| Haemoglobin decreased | 5 | 2.7% | 0 | 3 |
| Malaise | 5 | 2.7% | 1 | 1 |
| Rash | 5 | 2.7% | 0 | 1 |
Other Indications for VORAPAXAR
Product used for unknown indication (41)
Peripheral arterial occlusive disease (30)
Coronary artery disease (22)
Myocardial infarction (10)
Peripheral vascular disorder (5)
Other Drugs Used for Cardiovascular event prophylaxis
ATORVASTATIN (4,792)
LIPITOR (1,863)
ASPIRIN (950)
ASPIRIN DL-LYSINE (653)
CANAKINUMAB (560)
RIVAROXABAN (432)
CLOPIDOGREL BISULFATE (414)
TICAGRELOR (351)
SEMAGLUTIDE (207)
ICOSAPENT ETHYL (196)